IKS04 Regimen for Colorectal Cancer

Not yet recruiting at 3 trial locations
DB
Overseen ByDavid Browning
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Iksuda Therapeutics Ltd.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further evaluation in expansion (RDE). The regimen includes Isumab04 (unconjugated antibody) followed by the IKS04 antibody-drug conjugate, both directed against the CA242 (CanAg) tumor-associated antigen and administered intravenously (IV) in patients with advanced solid cancers.

Who Is on the Research Team?

JO

James O'Leary, MD

Principal Investigator

Iksuda Therapeutics Ltd.

Are You a Good Fit for This Trial?

This trial is for adults with advanced solid tumors (like colorectal, stomach, bile duct, or pancreatic cancer) that have the CA242 marker. Participants should be in generally stable health and able to receive IV treatments.

Inclusion Criteria

ANC ≥ 1500/mcL
AST/ALT ≤ 3 x institutional ULN or ≤ 5 x ULN if liver metastases present
Total bilirubin ≤ 1.5 x ULN unless participant has Gilbert's Syndrome
See 10 more

Exclusion Criteria

I have been treated with a CA242 ADC or a PBD ADC for my current cancer.
I have received more than 5 different treatments for my condition.
I have not taken strong CYP3A4 inhibitor medicines in the past week.
See 7 more

What Are the Treatments Tested in This Trial?

Interventions

  • IKS04 antibody-drug conjugate
  • Isumab04

Trial Overview

The study tests two new antibody-based drugs—Isumab04 and IKS04 ADC—given by IV. Both target the CA242 protein found on certain cancers. The main goal is to find a safe dose and see how well these drugs work against tumors.

How Is the Trial Designed?

5

Treatment groups

Experimental Treatment

Group I: Dose Expansion (Part II): CA242+ Gastro-Esophageal Adenocarcinoma ParticipantsExperimental Treatment1 Intervention
Group II: Dose Expansion (Part II): CA242+ Colorectal Cancer ParticipantsExperimental Treatment1 Intervention
Group III: Dose Expansion (Part II): CA242+ Biliary Tract Cancer ParticipantsExperimental Treatment1 Intervention
Group IV: Dose Expansion (Part II): CA242+ Advanced Solid Tumor Cancer ParticipantsExperimental Treatment1 Intervention
Group V: Dose Escalation Cohort (Part I)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Iksuda Therapeutics Ltd.

Lead Sponsor

Trials
2
Recruited
310+